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Abstract 
Purpose: To develop and validate a simple visible spectrophotometric method for the quantitative 
determination of ganciclovir in bulk sample and dosage form. 
Method: The method was based on the diazo coupling reaction between diazotized ganciclovir and 
acidified p-dimethylaminobenzaldehyde. Various analytical parameters for the azo adduct were 
established. Validation of the new method was carried out using current ICH guidelines with parameters 
including linearity, repeatability, reproducibility and selectivity determined. The developed method was 
thereafter applied to determine ganciclovir in a commonly available brand.   
Results: Coupling reaction generated a yellow-coloured product in an alcohol medium with optimal 
wavelength at 404 nm.  Linear correlation was obtained at concentrations of 10.3 - 25.7 µg/mL. The 
method was accurate and precise with recovery in the range of 99.37 - 103.15 % while intra- and inter-
day precision (% RSD) at three different concentrations was < 2.7 %.  The limits of detection and 
quantification were 0.23 and 0.70 µg/mL, respectively. When applied to the analysis of the dosage form, 
there was no statistically significant difference between the new method and the official HPLC method.   
Conclusion: The method is simple, inexpensive, reproducible and fast, and can be employed as a 
reliable alternative to the official method for the routine analysis of ganciclovir in bulk and dosage forms.   
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Ganciclovir was the first effective drug licensed 
for use in the prophylaxis of cytomegalovirus 
infections which remains the most frequently 
reported viral complication in patients receiving 
solid organ transplant [1,2]. 
 
Ganciclovir, a nucleoside analogue, is chemically 
known as 9-(1, 3-Dihydroxy-2-propoxymethyl) 
guanine and has a molecular weight of 255.2 
g/mol. Ganciclovir is equally active against 
Herpes simplex virus 1 and 2, Epstein-Barr virus, 
varicella zoster virus and Herpes 6, 7 and 8. Its 
mode of action involves its selective 
accumulation in infected cells, intracellular 
conversion to triphosphate by the viral enzymes 
(deoxyguanosine kinase, guanylate kinase, 
phosphoglycerate kinase) and the subsequent 
incorporation of the active triphosphate into viral 
DNA.  This leads to the inhibition of viral DNA 
synthesis following the inhibition of DNA 
polymerase enzyme [3,4]. 
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Literature review shows that a number of HPLC 
methods have been developed for the analysis of 
ganciclovir in biological sample matrices [5,6]. 
Although liquid chromatography with UV, 
fluorescence, mass spectrometry or 
electrochemical detection remains the most 
frequently used method, analysis by HPLC is 
often difficult because of the extensive retention 
of ganciclovir on non-polar stationary phases like 
C-18 reversed phase columns [7]. 
 
A number of alternative methods of analysis 
have been developed for the quantification of 
ganciclovir in bulk and dosage forms. These 
include spectrophotometric determination [8], 
voltammetry [9], reversed phase HPLC [10] and 
titrimetric quantification of unreacted oxidant 
following the oxidation of ganciclovir with cerium 
(IV) sulphate in acidic medium [11]. In the 
oxidimetric study, an alternative method of 
quantifying the unreacted oxidants following its 
reaction with p-dimethylaminobenzaldehyde to 
form a brown adduct with λmax of 460 nm was 
also described. Some visible spectrophotometric 
methods have been developed for the analysis of 
ganciclovir and include; the formation of different 
coloured products following the oxidation of 
ganciclovir with several inorganic oxidants [12] or 
charge-transfer complexation [13],  reaction of 
ganciclovir with quinalizarin reagent [14], 
oxidation with 1-fluoro-2, 4-dinitrobenzene or N-
Bromosuccinimide reagents [15]. 
   
Although the HPLC and immunoassay 
techniques described above remain the most 
frequently employed assay technique, they 
require sophisticated equipment that is not 
readily available in developing countries for 
routine analysis. Similarly, nearly all of the other 
described methods require drastic reaction 
conditions like use of buffer solutions, high 
concentration of mineral acids and extensive 
extraction procedures.  
 
In this present work, a simple visible 
spectrophotometric quantification of ganciclovir in 
bulk and dosage form is proposed and 
described. It is based on the formation of a 
yellow azo adduct following the coupling reaction 
between diazotized ganciclovir and p-
dimethylaminobenzaldehyde (DMAB). To the 
best of our knowledge, this represents the first 
reported method based on the utilization of 
diazotized ganciclovir as analyte.  The successful 
use of DMAB as a coupling reagent in the 
analytical determination of acyclovir [16] and 
many analytes of varied functionalities have been 
previously documented [17]. The new method is 
envisaged to provide an alternative approach to 






Lambda 25 with UV WinLab V2.85 software 
(Perkin Elmer USA), analytical balance (Ohaus 
Pioneer, Canada), thermostated water bath 
(Surgifriend, England) and vortex mixer (Griffins-
George, UK) were utilized in this study. 
 
Materials and reagents 
 
All solvents, salts and acids used in this study 
are of analytical grade including sodium nitrite, 
hydrochloric acid, sulphuric acid and sulphamic 
acid (BDH, UK), methanol (Sigma-Aldrich, 
Germany), DMAB (Aldrich, UK), sulphamic acid 
(Kemlight, India), Ganciclovir chemical reference, 
Ganguard® 500 mg (Ganciclovir sodium powder 
for injection Ranbaxy, India was purchased from 
a retail outlet in Lagos, Nigeria). Distilled water 
was used for all preparations and dilutions. A 
0.03 % DMAB in 0.0625 M sulphuric acid 
solution was prepared. 0.1 M sodium nitrite and 
0.2 M sulphamic acid solutions were also 
prepared.  
 
Preparation of standard solutions 
 
An accurately weighed amount (0.257 g) of pure 
reference ganciclovir was transferred into a 50 
mL volumetric flask, and dissolved in a small 
quantity of 0.1 M HCl. The resulting solution was 
then made up to volume with 0.1 M HCl to form 
the standard stock solution. A 514 µg/mL 
working solution was prepared by diluting 1 mL 
of the stock solution to 10 mL final volume with 




A 5 mL portion of ice-cold solution of ganciclovir 
was transferred into a 25 mL beaker. 1.5 mL of 
ice-cold 0.1 M sodium nitrite was added and the 
mixture stirred in an ice bath continuously for 10 
min. Thereafter, 0.2 mL of 0.2 M sulphamic acid 
was added to neutralize excess nitrous acid 
while the solution was continuously stirred until 
no more frothing was observed. Freshly prepared 
diazotized solution was used for the following 
experimental procedures. 
 
Evidence of coupling reaction 
 
The ability of DMAB to form azo adduct with 
diazotized ganciclovir was investigated as 
previously reported for acyclovir [16]. Evidence 
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for the reaction was established by spot test and 
thin layer chromatography (TLC). Reversed 
phase TLC was carried out using methanol: 
water (4:6) and normal phase mobile phases 
were ethyl acetate: methanol (9:1) and ethyl 
acetate: methanol (8:2).  The formation of new 
adduct or otherwise was determined by 
inspection of developed plates under the UV 
lamp. 
 
Optimization of reaction conditions 
 
The analytical wavelength was selected by the 
inspection of the overlaid absorption spectra of 
the drug, diazotized drug and the product of the 
coupling reaction between the diazotized drug 
and DMAB. The diazotization time and 
concentration of reagents employed were 
optimized for the development of maximum 
colour intensity. The optimization of the coupling 
temperature and time was carried out by the 
method of steepest ascent [18]. This was carried 
out at temperatures of 30, 50, 60, 70 and 80 oC 
after incubation times of 5 and 10 min at each 
temperature level. The optimum time required for 
coupling at the selected temperature, 60 oC was 
determined by carrying out reactions at 0, 2, 5, 
10, 15, 20, 25 and 30 min.  
 
Stoichiometric determination using the Job’s 
method of continuous variation [19] 
 
For this determination, increasing volumes 
between 0 and 1.0 mL of the diazotized 
ganciclovir was made up to 1 mL with 
appropriate amounts of DMAB solution. The 
reaction mixture was vortex mixed for 10 s and 
maintained at 60 oC for 10 min. The reaction was 
then stopped by cooling in ice and the volume of 
the solution made up to 5 mL with methanol. The 
absorbance readings were taken at 404 nm with 
methanol as the blank solvent. All determinations 
were carried out in duplicate. 
 
Validation of the new method of analysis 
 
The calibration line was generated from the 3-
day average of curves using 0, 0.1, 0.12, 0.15, 
0.2 and 0.25 mL (equivalent to 0, 10.26, 12.31, 
15.39, 20.52 and 25.65 µg/mL) of the diazotized 
drug. 0.5 mL DMAB solution was added to each 
test tube, vortex mixed for 10 sec and the 
mixture maintained at 60 oC for 10 min. 
Thereafter, the reaction was stopped with cooling 
in ice and each reaction mixture was made up to 
5 mL with the required volume of methanol. The 
absorbance reading was taken at 404 nm with 
methanol as blank. Each determination was 
carried out in triplicate. 
 
The suitability of the proposed method for the 
assay of ganciclovir was examined by 
determining the model recoveries and 
repeatability of the method on three successive 
days as stipulated by the ICH [20]. The intra- and 
inter-day accuracies and precisions of the 
proposed method were assessed from the 
results of replicate analyses on the pure drug 
solutions. The mean values and relative standard 
deviations for replicate analyses at three different 
concentration levels were calculated. The limit of 
detection (LOD) and limit of quantification (LOQ) 
were calculated as 3.3 σ/S and 10 σ/S 
respectively where, σ is the standard deviation of 
the absorbance of blank (n = 6) and S is the 




The selectivity of the new method was examined 
by determining the recovery of the diazotized 
drug (17.4 µg/mL) in sample matrices containing 
the commonly used pharmaceutical aids; starch, 
lactose, magnesium stearate, talc and gelatin. 
 
Assay of dosage form 
 
An accurately weighed amount of the powder for 
injection equivalent to 0.513 g ganciclovir was 
transferred to a 100 mL standard flask and 
dissolved in a small quantity of 0.1 M HCl. The 
solution was then made up to volume with 0.1 M 
HCl. A final working solution was prepared by 
diluting 1 mL of the stock solution to 10 mL with 
0.1 M HCl. The resulting solution of the analyte 
was subsequently used for diazotization as 
described in the procedure above.  
 
A 0.17 mL aliquot of the diazotized solution 
(equivalent to 17.4 µg/mL ganciclovir) was mixed 
with 0.5 mL of 0.03 % DMAB solution using a 
vortex mixer for 10 s. The reaction was 
maintained at 60 oC for 10 min and thereafter 
stopped by cooling in ice and then made up to 5 
mL with methanol. The absorbance reading was 
taken at 404 nm.  
 
The official HPLC method of assay of ganciclovir 
was also carried out on the dosage form [21]. Six 





Evidence of coupling reaction  
 
The formation of a new product following 
coupling was established with spot test and TLC 
analysis of the reaction mixture. The diazotized 
ganciclovir gave an instant yellow adduct with 
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DMAB. This new colour was quite distinct from 
the colorless solutions of ganciclovir, its 
diazonium salt or DMAB. Similar results were 
observed after incubation at elevated 
temperature (70 oC) and prolonged time (20 
min). The intensity of the yellow product was 
stable for more than 4 h when monitored by its 
absorbance. Normal-phase and reversed-phase 
TLC analysis of the adduct in three different 
mobile phases showed the formation of a single 
product with retardation factor, Rf values distinct 
from those of the diazotized ganciclovir and 
DMAB.   
 
Selection of analytical wavelength 
 
The overlaid spectra of ganciclovir, its diazotized 
derivative and the azo adduct formed between 
diazotized ganciclovir and DMAB are presented 
in Figure 1. 
 
Optimization of reaction variables 
 
Development of colour intensity 
 
The concentration of the acids used in 
preparation of DMAB and ganciclovir stock 
solutions was found to be critical in the coupling 
reaction for the formation of optimal colour 
intensity. Similarly, the amount and concentration 
of sulphamic acid used in the removal of excess 
nitrous acid at the completion of diazotization 
was also critical as an excess or a complete 
change to urea led to reduction in colour 
intensity. Thus, the optimal acid concentration 
was found to be 0.0625 M while the amount of 
sulphamic acid used for stopping the 
diazotization reaction was kept at optimum value 
of 0.2 ml of 0.2 M solution all the time.  
 
Selection of coupling temperature and time    
 
The optimal reaction temperature and heating 
time were established at 60 oC and 10 min 
respectively. Heating temperatures or time led to 
decrease in the absorbance which is probably 
due to the thermal decomposition of the coupling 
product.  
 
Stoichiometric ratio and reaction mechanism 
 
The highest absorbance values were obtained at 
1:1 ratio indicating only the presence of one 
diazotizable group in ganciclovir. With this result 
and coupled with observation of the presence of 
a single spot in the TLC analysis of the reaction 
mixture, a 1:1 azo adduct formation is proposed 
as the underlying basis for the reaction 
mechanism.  
 
Validation of the new method 
 
Linearity and calibration line 
 
A linear correlation was obtained at wavelength 
of 404 nm and at concentrations of 10.3-25.7 




Figure 1: Overlaid spectra of ganciclovir (■), diazotized ganciclovir (♦) and adduct (▲) 
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The correlation coefficient was very close to 
unity. The 95 % confidence limits for the slope 
and the intercept depicted the suitability of the 
method for the proposed analytical utility. 
Likewise, the lowest limits of detection and 
quantitation compared favorably with previously 
reported methods for ganciclovir. The various 
analytical parameters are presented in Table 1. 
 
Table 1: Analytical and validation parameters for the 
new method 
  
Performance parameter Value 
Beer’s Law Limit (µg/mL) 10.3- 25.7 
Limit of detection (µg/mL)  0.23 
Limit of quantification (µg/mL) 0.70 
Molar absorptivity (L mol-1 cm-1) 8.7x103 
Sandell’s sensitivity (μg cm-2 per 
0.001 A) 
0.033 
Slope ± SD 0.0304 ±2.52x10-4 
Intercept ± SD 0.0399±0.011 
Correlation coefficient 0.999 
Coefficient of determination 0.998 
 
Assessment of accuracy and precision of the 
proposed method for ganciclovir 
 
The results for the intra- and inter-day accuracy 
and precision of the new spectrophotometric 
method are presented in Table 2. The results 
show the new method having a percentage 
recovery of 98.4-103.2 % and percentage 
relative error of 3.14 %. This projects the new 
method as accurate since the relative error is 
less than 5 %. The method also showed good 
repeatability as the percentage RSD did not 
exceed 2.4 %. 
 
For the inter-day results, the percentage 
recovery and percentage relative error of the new 
method were 98.9-102.6 % and 2.6 % 
respectively indicating high accuracy. Similarly, 
the percentage relative standard deviation did 




The recovery of ganciclovir in the presence of the 
excipients was between 95.3 % and 102.9 % 
indicating good selectivity of the method and 
hence depicting lack of interference by 
commonly used excipients in dosage forms.  
 
Assay of dosage form and comparison of 
performance with official method  
 
The new method was applied to the content 
analysis of the available ganciclovir injectable 
preparation. The results obtained as well as the 
comparison of the performance parameters of 
the new and official methods are presented in 
Table 3. With both methods, the label claims of 
the active content were within the specified limits 




The reaction of diazotized ganciclovir with DMAB 
gave an instant yellow-colored solution. The 
formation of the color depicts the presence of 
new chemical species which was proven through 
the TLC analysis of the reaction mixture.  
 
On investigating the spectral patterns (Figure 1) 
of the various species involved in this new 
method, ganciclovir has well-defined absorption 
peaks at 215 and 250 nm while DMAB has 
prominent peaks at 215, 250, 300 and 350 nm. 
On diazotizing ganciclovir, the absorption peak at 
215 nm was maintained with a slight 
bathochromic shift of the 250 nm peak (∆λ = +5 
nm) to 255 nm. 
 


















12.31 99.37±0.16 1.34 0.63 99.79±0.38 3.11 0.21 
17.44 103.15±0.4 2.37 3.14 102.64±0.40 2.11 2.63 
23.60 98.36±0.44 1.85 1.64 98.91±0.56 2.38 1.09 
*n=4 for each concentration level, ** n=12 for each concentration (average of three days) 
 
Table 3: Comparative analytical data for dosage form of drug based on the proposed and official HPLC methods 
 
 New method HPLC method Statistical data 













Ganguard®  0.53 3.78 0.55 4.98 96.4 0.54 0.16 
*ratio of the results obtained with the new method to that of the official method 
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However, following the coupling reaction of 
diazotized ganciclovir with DMAB, a completely 
different UV absorption spectrum was obtained. 
There was a marked bathochromic and 
hyperchromic shifts of the spectrum of the new 
adduct relative to the diazotized ganciclovir and 
DMAB with prominent peaks at 235 and 335 nm 
and a shoulder at 400 nm. Optimal difference in 
absorptivity was observed when absorbance 
measurements were recorded at 404 nm. This 
wavelength (404 nm) was therefore selected as 
analytical wavelength as it showed little or no 
background absorptivity from interfering 
components in the sample matrix.   
 
The proposed method is based on the coupling 
reaction between the generated diazonium ion 
which was reactive towards activated ring 
systems such as p-DMAB.  Optimal reaction was 
facilitated at an elevated temperature. Elevated 
temperature has been found to be useful for the 
utilization of DMAB in coupling reaction since the 
diazonium ion generated from the drug was not 
intensely reactive compared to conventional 
benzene diazonium ions.  
 
The coupling reagent consists of an aromatic 
system sandwiched between an electron donor 
and acceptor. The electronic effect of DMAB was 
therefore significantly improved by the 
contributions of its two canonical structures (the 
neutral benzenoid structure and the zwitterionic 
quinonoid structure with negative and positive 
charges on the oxygen and nitrogen respectively) 
in the electronic ground state.  In addition, a 
combined influence of the activating ortho-
directing tertiary amino group and the meta-
directing aldehyde group made the 3- and 5- 
positions on the DMAB moiety available to an 
incoming electrophile. The successful use of 
DMAB as coupling agent for diazotizable groups 
including primary amino groups and reducible 
nitro groups present on aromatic skeletons have 
been demonstrated [16,22]. As previously 
reported, the utilization of alcoholic solution 
(particularly methanol) repressed the 
deactivating influence of aldehyde group while 
the activating potential of the dimethylamino 
group was optimal. This led to ready substitution 
of the incoming electrophile and hence formation 
of a yellow-colored solution. The proposed 
coupling reaction pattern of the new method is 
depicted in Figure 2. 
 
Following the optimization studies for the 
formation of the new azo adduct between DMAB 
and diazotized ganciclovir, a comparative study 
of the suitability of the new method to assay the 
drug in a dosage form was carried out alongside 
the official HPLC method. A statistical 
comparison using the F-ratio and Student’s t-
tests did not reveal any difference between the 
official and the new methods. The F test did not 
show any variance between the two methods 
while the t-test did not reveal any statistically 
significant difference in their recoveries. The two 
tests therefore showed no statistically significant 
differences between the precision and accuracy 
of the two methods and established the proposed 
method as a reliable alternative to the official 
method.  However, the new method exhibited 
some greater advantages over the HPLC 
method. 
 
Figure 2: Proposed coupling reaction pattern between diazotized ganciclovir and DMAB 
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Compared to the official HPLC assay, the new 
method is simple, inexpensive and faster 
because of the long retention of ganciclovir on 
HPLC columns. The performance of the new 
method also compared favorably with other UV 
visible methods with the added advantage of 
employing readily available, affordable and 
chemically stable reagents. The DMAB solution 
produced reproducible results for up to 7 days 
and 14 days when stored at room temperature 




A new visible spectrophotometric method for the 
quantification of ganciclovir has been developed 
and validated. The method can serve as a 
reliable and affordable assay method for the 





1. Perrottet N, Decosterd  LA, Meylan  P, Pascual  M, 
Biollaz J, Buclin T. Valganciclovir in adult solid organ 
transplant recipients: pharmacokinetic and 
pharmacodynamic characteristics and clinical 
interpretation of plasma concentration 
measurements. Clin Pharmacokinet. 2009; 48: 399-
418. 
2. Asberg A, Rollag H, Hartmann A. Valganciclovir for the 
prevention and treatment of CMV in solid organ 
transplant recipients. Expert Opin Pharmacother. 
2010; 11: 1159-1166. 
3. Matthews T, Boehme R.  Antiviral activity and mechanism 
of action of ganciclovir. Rev Infect Dis. 1988; 10: 
S490-S494. 
4. Martindale The Complete Drug Reference ed 36. London, 
Pharmaceutical Press, 2009. 
5. Padulles  A, Colom H, Armendariz  Y, Cerezo  G, Caldes  
A, Pou L, Torras J, Grinyo  JM, Lloberas N. 
Determination of ganciclovir in human plasma by ultra 
performance liquid chromatography–UV detection. 
Clin Biochem. 2012; 45: 309-314. 
6. Merodio M, Campanero MA, Mirshahi T, Mirshahi M, 
Irache JM. Development of a sensitive method for the 
determination of ganciclovir by reversed-phase high-
performance liquid chromatography. J Chromatogr. 
2000; 870: 159-167. 
7. Boscha ME, Sánchezb A J, Rojasc FS, Ojedac CB. 
Ganciclovir: a review of its analytical determination. 
AJPS 2009; 4: 254-264. 
8. Reddy CM, Reddy GV. Determination of ganciclovir in 
bulk and pharmaceutical dosage forms by UV 
spectromphotometric method. Int Res J Pharm. 2012; 
3: 286-288. 
9. Uslu B, Doğan B, Ozkan SA. Electrochemical studies of 
ganciclovir at glassy carbon electrodes and its direct 
determination in serum and pharmaceutics by square 
wave and differential pulse voltammetry. Anal chim 
acta 2005; 537: 307-313. 
10. Sarsambi PS, Sonawane A, Faheem A. Development 
and validation of RP-HPLC method for the 
determination of ganciclovir in bulk drug and its 
formulations. Int J Pharm. Bio. Sci. 2010; 1: 1-7. 
11. Ramesh PJ, Basavaiah K, Xavier CM, Prashanth KN, 
Raghu MS, Vinay KB. Titrimetric and 
Spectrophotometric Assay of Ganciclovir in 
Pharmaceuticals Using Cerium (IV) Sulphate as the 
Oxidimetric Agent. ISRN Anal Chem. 2012: 1-8. 
12. Gouda AA, Amin AS. Utility of inorganic oxidants for the 
spectrophotometric determination of ganciclovir in 
dosage forms. Lat. Am. J. Pharm. 2011; 30: 334-341. 
13. Gouda AA. Utility of certain sigma- and pi-acceptors for 
the spectrophotometric determination of ganciclovir in 
pharmaceutical formulations. Talanta 2009; 80: 151-
157. 
14. Al-Neaimy UI, Al-Delymi AMS. Visible 
Spectrophotometric Determination of Ganciclovir in 
its Pharmaceutical Formulations using Quinalizarin 
Reagent. Jord J Chem. 2013; 8: 103-112. 
15. Kumar TA, Gurupadayya BM, Reddy MBR. Selective and 
Validated Spectrophotometric Assay for Microgram 
Determination of Ganciclovir with 1-fluoro-2, 4-
dinitrobenzene and N-Bromosuccinimide Reagents. J 
Appl Chem Res. 2012; 20: 14-27. 
16. Thomas OE, Adegoke OA. Development and validation 
of a new spectrophotometric method for the 
determination of acyclovir. J Pharmacy & 
Bioresources 2012; 9: 75-84. 
17. Adegoke OA. Analytical, biochemical and synthetic 
applications of para-dimethylaminobenzaldehyde. Int 
J Pharm Sci Rev Res. 2011; 11: 17-29. 
18. Karnes HT, March C. Precision, accuracy and data 
acceptance criteria in biopharmaceutical analysis. 
Pharm. Res. 1993; 10: 1420-1426. 
19. Rose J. Advanced Physico-Chemical Experiments. 
London: Pitman; 1964 p. 52. 
20. ICH Guidelines Q2 (R1). Validation of Analytical 
Procedures: Text and Methodology. Date accessed 
20 June 2013. 
21. United States Pharmacopoeia 30/National Formulary 25. 
Rockville,Md., USA, 2007. 
22. Adegoke OA, Umoh OE. A new approach to the 
spectrophotometric determination of metronidazole 
and tinidazole using p- dimethylaminobenzaldehyde. 
Acta Pharm. 2009; 59: 407-419. 
 
